View Post

HER2-Directed Therapies Continue to Shape Improved Breast Cancer Outcomes

In In The News by Barbara Jacoby

By: Ashling Wahner From: onclive.com As the treatment of HER2 in breast cancer becomes better defined, the HER2-directed antibody trastuzumab (Herceptin) has earned a place as a standard agent in several stages of HER2-positive disease, and additional HER2-targeted drugs may build on historical treatment successes achieved with this agent, according to Debu Tripathy, MD. “The early studies of trastuzumab in …

View Post

T-DXd Emerges as Top Pick For HER2+ Breast Cancer

In In The News by Barbara Jacoby

By: Morgan Bayer From: targetedonc.com As a second-line option, trastuzumab deruxtecan (Enhertu; T-DXd) has become a preferred treatment choice in the management of HER2- positive metastatic breast cancer based on updates from the DESTINY-Breast03 trial (NCT03529110). Trial investigators reported that the median progression-free survival (PFS) was about 4 times longer using T-DXd (28.8 months; 95% CI, 22.4-37.9) when compared with …

View Post

Managing HER2+ Early Breast Cancer: A Focus on Target Therapy

In In The News by Barbara Jacoby

From: targetedonc.com New breast cancer diagnoses account for 31% of annual cancer diagnoses among women in the United States.1 Among those diagnoses, HER2 overexpression is observed in 25% to 30% of cases. Historically, HER2-positive (HER2+) breast cancer was considered an aggressive subtype and was associated with a poor prognosis; however, the emergence of HER2-targeted therapies such as trastuzumab has considerably …

View Post

HERO (*Her2 Radiation Optimization) Study: New Breast Cancer Study Seeks to Optimize use of Radiotherapy in Patients with Early- Stage, Low Risk, HER2-Positive Breast Cancer

In In The News by Barbara Jacoby

New Breast Cancer Study Seeks to Optimize use of Radiotherapy in Patients with Early- Stage, Low Risk, HER2-Positive Breast Cancer NRG-BR008, also known as the “HERO” trial, is a clinical study trying to determine if treatment with HER2-targeted therapy without radiation therapy is as good as the usual treatment of HER2-targeted therapy with radiation in patients with early-stage HER2-positive breast …

View Post

New treatment breakthrough: Pyrotinib combo demonstrates remarkable efficacy for HER2 positive metastatic breast cancer

In In The News by Barbara Jacoby

By: By Dr. Chinta Sidharthan From: news-medical.net In a recent study published in the BMJ Journal, a team of scientists from China investigated the safety and efficacy of treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with pyrotinib, a pan-HER inhibitor, in combination with docetaxel and trastuzumab, and compared it to that of a variety of a …

View Post

Looking Forward in the HER2-Positive Breast Cancer Space

In In The News by Barbara Jacoby

By: Hatem Soliman, MD From: targetedonc.com Hatem Soliman, MD, medical oncologist in The Center for Women’s Oncology and assistant member of the Experimental Therapeutics Program at Moffitt Cancer Center, discusses some of the exciting research that is ongoing for patients with HER2-positive breast cancer. The HER2-positive metastatic breast cancer space has had a variety of new therapies come into play …

View Post

RNI Omission Yields Low Locoregional Recurrence in HR+, HER2– Breast Cancer

In In The News by Barbara Jacoby

By: Russ Conroy From: cancernetwork.com Locoregional recurrence (LRR) rates appeared to be low among patients with hormone receptor (HR)–positive, ERBB2-negative breast cancer who did not receive regional node irradiation (RNI), according to findings from a secondary analysis of the SWOG S1007 trial. After a median follow-up of 6.1 years, the cumulative incidence of LRR was 0.85% in patients who underwent …

View Post

HER2+ Breast Cancer Treatment Arena May Redefine the Roles of ADCs and Targeted Agents

In In The News by Barbara Jacoby

By: Ashling Wahner From: onclive.com The expansion of the HER2-positive breast cancer treatment landscape hinges on defined treatment sequencing in the later-line setting and further research investigating the safety and efficacy of antibody-drug conjugates (ADCs) in combination with tucatinib (Tukysa), according to Adrienne G. Waks, MD. The phase 3 HER2CLIMB-02 trial (NCT03975647) is investigating ado-trastuzumab emtansine (Kadcyla) with or without …

View Post

Dr Waks on Survival Outcomes With Chemotherapy in Small Node-Negative HER2+ Breast Cancer

In In The News by Barbara Jacoby

By: Adrienne G. Waks, MD From: onclive.com Adrienne G. Waks, MD, physician, associate director of Clinical Research, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses breast cancer survival in patients with small node-negative HER2-positive breast cancer according to the treatment modality received. An analysis of treatment patterns and patient outcomes was conducted to clarify the benefit of systemic …

View Post

Soliman Details Testing for and Treating HER2+ Breast Cancer

In In The News by Barbara Jacoby

By: Jordyn Sava From: targetedonc.com Over recent years, patients with HER2-positive metastatic breast cancer now have new therapies which have changed the treatment landscape in this space based on the completed and ongoing trials. The phase 3 CLEOPATRA study (NCT00567190), the efficacy and safety of pertuzumab (Perjeta), trastuzumab (Herceptin), and docetaxel was compared with placebo, trastuzumab, and docetaxel in patients …